Braxia Scientific (Seite 2)
eröffnet am 18.05.21 10:24:40 von
neuester Beitrag 07.04.24 04:14:20 von
neuester Beitrag 07.04.24 04:14:20 von
Beiträge: 225
ID: 1.347.745
ID: 1.347.745
Aufrufe heute: 0
Gesamt: 36.213
Gesamt: 36.213
Aktive User: 0
ISIN: CA1057361026 · WKN: A3CPBM · Symbol: BRAX
0,0100
CAD
+100,00 %
+0,0050 CAD
Letzter Kurs 08.05.24 CSE
Neuigkeiten
Werte aus der Branche Getränke/Tabak
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,1400 | +81,50 | |
| 10,000 | +25,00 | |
| 1,4100 | +18,39 | |
| 3,8800 | +14,12 | |
| 31,77 | +11,79 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 940,00 | -6,87 | |
| 2,5600 | -6,91 | |
| 4,2100 | -7,06 | |
| 0,8558 | -17,71 | |
| 1,2900 | -41,36 |
Beitrag zu dieser Diskussion schreiben
Feedback
Braxia Scientific Reports Q3 2023 Financial Results and Provides Update on Acquisition Under LOI with Irwin Naturals
Published on March 1, 2023
https://braxiascientific.com/news/braxia-scientific-reports-…
Braxia Scientific Q3 2023 Financial Summary and Recent Highlights
Q3 2023 Braxia Health in-clinic ketamine treatments increased 29% year-over-year. In the first 9 months of 2023, in-clinic treatments increased 30% compared to the prior year period.
Q3 2023 revenue increased 50.5% year-over-year to $0.48 million for the period ending December 31, 2022. In first nine months of 2023, revenues increased 21.9% to $1.36 million compared to prior year period.
Braxia Health’s clinic performance is expected to see steady improvement as three new clinics, Ottawa, Toronto and Kitchener-Waterloo, continue to ramp up operations and deploy new technology to drive patient acquisition and fill newly added capacity. Additionally, Braxia’s Toronto clinic has commenced psilocybin treatments under its special access program which is expected to continue to ramp up in 2023.
During the quarter, KetaMD, the Company’s U.S. telemedicine platform, continued to expand the initial pilot of its virtual ketamine treatments along with multiple marketing initiatives to drive new patient referrals. Additionally, the KetaMD has made excellent progress in building a pipeline of potential clinic partnerships.
Net loss was $2.17 million for the three months ended December 31, 2022, compared to a net loss of $2.5 million for the three months ended December 31, 2021. Net loss during the quarter includes non-cash share-based compensation of $0.15 million.
In the first nine months of 2023, net loss was $5.48 million compared to a net loss of $5.32 million in the prior year period. Net loss includes non-cash share-based compensation of $0.75 million.
As at December 31, 2022, the Company’s cash and cash equivalents were $1.49 million and working capital was $0.72 million. Subsequent to the quarter-end, the Company completed a non-brokered offering which closed February 27, 2023 resulting in aggregate proceeds of $1.26 million.
The Company is pleased to report it received final court approval on February 28, 2023, on terms previously disclosed, to settle claims alleged in a securities class action (the “US Class Action”) against the Company and certain of its former officers filed in the United States District Court for the Central District of California in April 2021.
Published on March 1, 2023
https://braxiascientific.com/news/braxia-scientific-reports-…
Braxia Scientific Q3 2023 Financial Summary and Recent Highlights
Q3 2023 Braxia Health in-clinic ketamine treatments increased 29% year-over-year. In the first 9 months of 2023, in-clinic treatments increased 30% compared to the prior year period.
Q3 2023 revenue increased 50.5% year-over-year to $0.48 million for the period ending December 31, 2022. In first nine months of 2023, revenues increased 21.9% to $1.36 million compared to prior year period.
Braxia Health’s clinic performance is expected to see steady improvement as three new clinics, Ottawa, Toronto and Kitchener-Waterloo, continue to ramp up operations and deploy new technology to drive patient acquisition and fill newly added capacity. Additionally, Braxia’s Toronto clinic has commenced psilocybin treatments under its special access program which is expected to continue to ramp up in 2023.
During the quarter, KetaMD, the Company’s U.S. telemedicine platform, continued to expand the initial pilot of its virtual ketamine treatments along with multiple marketing initiatives to drive new patient referrals. Additionally, the KetaMD has made excellent progress in building a pipeline of potential clinic partnerships.
Net loss was $2.17 million for the three months ended December 31, 2022, compared to a net loss of $2.5 million for the three months ended December 31, 2021. Net loss during the quarter includes non-cash share-based compensation of $0.15 million.
In the first nine months of 2023, net loss was $5.48 million compared to a net loss of $5.32 million in the prior year period. Net loss includes non-cash share-based compensation of $0.75 million.
As at December 31, 2022, the Company’s cash and cash equivalents were $1.49 million and working capital was $0.72 million. Subsequent to the quarter-end, the Company completed a non-brokered offering which closed February 27, 2023 resulting in aggregate proceeds of $1.26 million.
The Company is pleased to report it received final court approval on February 28, 2023, on terms previously disclosed, to settle claims alleged in a securities class action (the “US Class Action”) against the Company and certain of its former officers filed in the United States District Court for the Central District of California in April 2021.
Braxia Scientific Announces Closing of First Tranche of LIFE Offering and Concurrent Private Placement
Published on February 27, 2023
https://braxiascientific.com/news/braxia-scientific-announce…
Published on February 27, 2023
https://braxiascientific.com/news/braxia-scientific-announce…
Braxia Scientific Announces Offering up to $1.5 Million, Braxia Management to Participate in Concurrent Private Placement
Published on February 7, 2023
https://braxiascientific.com/news/braxia-scientific-announce…
Not fixed yet you will be the owner.
Published on February 7, 2023
https://braxiascientific.com/news/braxia-scientific-announce…
Not fixed yet you will be the owner.
Dann haben wir also bald Irwin shares auf dem Konto und keine Braxia Scientific mehr.
1 Irwin fuer 76 Braxia im worst case und als Basis die 0.05CAD.
30.000.000USD (valuation of Braxia outstanding shares) /240.720.000Shares (total Aktiananzahl))= 0.124 USD per share (wenn alle Aktien outstanding waeren).
1 Irwin fuer ~30 Braxia im case of 0.124CAD
Naja, ca. 6 Monate spaeter wissen wir mehr.
1 Irwin fuer 76 Braxia im worst case und als Basis die 0.05CAD.
30.000.000USD (valuation of Braxia outstanding shares) /240.720.000Shares (total Aktiananzahl))= 0.124 USD per share (wenn alle Aktien outstanding waeren).
1 Irwin fuer ~30 Braxia im case of 0.124CAD
Naja, ca. 6 Monate spaeter wissen wir mehr.
Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific
January 27, 2023
Toronto, Ontario--(Newsfile Corp. - January 27, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia ", or the "Company") a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce it has entered into a non-binding amended and restated letter of intent ("LOI") for a business combination with Irwin Naturals Inc. (CSE: IWIN) (OTCQB: IWINF) (FSE: 97X) ("Irwin") . Irwin has been one of North America's leading health and wellness companies for nearly three decades and has recently developed a rapidly growing network of mental health clinics in the US. The LOI sets forth the material terms and conditions upon which Irwin will acquire all of the issued and outstanding common shares (the "Braxia Shares") of Braxia (the "Proposed Transaction").
Under the terms of the LOI, Irwin is prepared to offer a purchase price per Braxia Share based upon a valuation of the outstanding Braxia Shares of US$30,000,000 and a deemed value per subordinate voting share ("Irwin Share") and/or proportionate voting share of Irwin ("Consideration Shares") equal to the greater of US$3.00 and the volume weighted average trading price of Irwin Shares on the Canadian Securities Exchange (the "CSE") for the 20 trading days immediately prior to the execution of the Arrangement Agreement. The purchase price would be payable on closing of the Proposed Transaction (the "Closing Date") by the issuance of Consideration Shares to each holder of Braxia Shares. Based on the closing price of Irwin Shares and Braxia Shares on the CSE on January 25, 2023 of C$3.80 and C$0.05, respectively, the purchase price and exchange ratio imply a 315.72% premium to the price of Braxia Shares. The number of Consideration Shares will also be adjusted upward in the event that the total consideration received by holders of Braxia Shares is less than US$30,000,000, to be determined at a specified period of time after the Closing Date and as set forth in the Arrangement Agreement.
https://www.psychedelicfinance.com/articles/irwin-naturals-s…
January 27, 2023
Toronto, Ontario--(Newsfile Corp. - January 27, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia ", or the "Company") a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce it has entered into a non-binding amended and restated letter of intent ("LOI") for a business combination with Irwin Naturals Inc. (CSE: IWIN) (OTCQB: IWINF) (FSE: 97X) ("Irwin") . Irwin has been one of North America's leading health and wellness companies for nearly three decades and has recently developed a rapidly growing network of mental health clinics in the US. The LOI sets forth the material terms and conditions upon which Irwin will acquire all of the issued and outstanding common shares (the "Braxia Shares") of Braxia (the "Proposed Transaction").
Under the terms of the LOI, Irwin is prepared to offer a purchase price per Braxia Share based upon a valuation of the outstanding Braxia Shares of US$30,000,000 and a deemed value per subordinate voting share ("Irwin Share") and/or proportionate voting share of Irwin ("Consideration Shares") equal to the greater of US$3.00 and the volume weighted average trading price of Irwin Shares on the Canadian Securities Exchange (the "CSE") for the 20 trading days immediately prior to the execution of the Arrangement Agreement. The purchase price would be payable on closing of the Proposed Transaction (the "Closing Date") by the issuance of Consideration Shares to each holder of Braxia Shares. Based on the closing price of Irwin Shares and Braxia Shares on the CSE on January 25, 2023 of C$3.80 and C$0.05, respectively, the purchase price and exchange ratio imply a 315.72% premium to the price of Braxia Shares. The number of Consideration Shares will also be adjusted upward in the event that the total consideration received by holders of Braxia Shares is less than US$30,000,000, to be determined at a specified period of time after the Closing Date and as set forth in the Arrangement Agreement.
https://www.psychedelicfinance.com/articles/irwin-naturals-s…
Trading Spotlight
Q2 2023 Financial Summary
- Q2 2023 in-clinic treatments increased 34.5% year-over-year. In first 6 months of 2023, in-clinic treatments increased 35% compared to the prior year period.
- During the quarter, the Company acquired KetaMD which launched an initial pilot of its virtual ketamine treatments late in the quarter. The Company expects KetaMD’s revenues and profitability to increase as services and operations ramp up services, marketing and forge new clinical partnerships.
- Q2 2023 revenue increased 18% year-over-year to $0.46 million for the period ending September 30, 2022.
- In first six months of 2023, revenues increased 10.1% to $0.87 million compared to prior year period.
- Net loss was $2.2 million for Q2 2023 ended September 30, 2022, compared to a net loss of $1.7 million for the three months ended September 30, 2021. Net loss during the quarter includes non-cash share-based compensation of $0.38 million and $0.25 million from the fair value change of convertible debenture pursuant to the acquisition of KetaMD.
- In first six months of 2023, net loss was $3.1 million compared to a net loss of $2.8 million in the prior year period. Net loss includes non-cash share-based compensation of $0.6 million.
- As at September 30, 2022, the Company’s cash and cash equivalents were $5.2 million and working capital was $2.32 million.
- The Company is in discussions with various parties to explore sources of funding and partnerships to further its growth initiatives, including the expansion of KetaMD.
https://braxiascientific.com/news/braxia-scientific-reports-…
- Q2 2023 in-clinic treatments increased 34.5% year-over-year. In first 6 months of 2023, in-clinic treatments increased 35% compared to the prior year period.
- During the quarter, the Company acquired KetaMD which launched an initial pilot of its virtual ketamine treatments late in the quarter. The Company expects KetaMD’s revenues and profitability to increase as services and operations ramp up services, marketing and forge new clinical partnerships.
- Q2 2023 revenue increased 18% year-over-year to $0.46 million for the period ending September 30, 2022.
- In first six months of 2023, revenues increased 10.1% to $0.87 million compared to prior year period.
- Net loss was $2.2 million for Q2 2023 ended September 30, 2022, compared to a net loss of $1.7 million for the three months ended September 30, 2021. Net loss during the quarter includes non-cash share-based compensation of $0.38 million and $0.25 million from the fair value change of convertible debenture pursuant to the acquisition of KetaMD.
- In first six months of 2023, net loss was $3.1 million compared to a net loss of $2.8 million in the prior year period. Net loss includes non-cash share-based compensation of $0.6 million.
- As at September 30, 2022, the Company’s cash and cash equivalents were $5.2 million and working capital was $2.32 million.
- The Company is in discussions with various parties to explore sources of funding and partnerships to further its growth initiatives, including the expansion of KetaMD.
https://braxiascientific.com/news/braxia-scientific-reports-…
Braxia Scientific holders approve all matters at AGSM
2022-11-01 18:44 ET - News Release
Dr. Roger McIntyre reports
BRAXIA SCIENTIFIC ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
Braxia Scientific Corp. has released the voting results from its annual general and special meeting of shareholders held on Monday, Oct. 31, 2022. A total of 16.55 per cent of the issued and outstanding common shares of the company were represented either in person or by proxy at the meeting.
On a vote by ballot, the four nominees as shown in the attached table, proposed by the company, were elected as directors of Braxia Scientific to serve until the company's next annual meeting of shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as shown in the attached table.
In addition to the election of all nominees listed as directors in the management information circular, dated Sept. 16, 2022, Braxia shareholders approved all other resolutions placed before the meeting. These included appointing DMCL as auditor for the company for the ensuing year and approving an amendment to the company's stock option plan dated Oct. 15, 2019, as set forth in the circular.
For more details on the matters covered at the annual meeting, please refer to the company's management information circular available on SEDAR. Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.
https://www.stockwatch.com/News/Item/Z-C!BRAX-3322639/C/BRAX
2022-11-01 18:44 ET - News Release
Dr. Roger McIntyre reports
BRAXIA SCIENTIFIC ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
Braxia Scientific Corp. has released the voting results from its annual general and special meeting of shareholders held on Monday, Oct. 31, 2022. A total of 16.55 per cent of the issued and outstanding common shares of the company were represented either in person or by proxy at the meeting.
On a vote by ballot, the four nominees as shown in the attached table, proposed by the company, were elected as directors of Braxia Scientific to serve until the company's next annual meeting of shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as shown in the attached table.
In addition to the election of all nominees listed as directors in the management information circular, dated Sept. 16, 2022, Braxia shareholders approved all other resolutions placed before the meeting. These included appointing DMCL as auditor for the company for the ensuing year and approving an amendment to the company's stock option plan dated Oct. 15, 2019, as set forth in the circular.
For more details on the matters covered at the annual meeting, please refer to the company's management information circular available on SEDAR. Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.
https://www.stockwatch.com/News/Item/Z-C!BRAX-3322639/C/BRAX
Braxia to pay $1.36M out of pocket to settle lawsuits
2022-09-16 20:31 ET - News Release
Dr. Roger McIntyre reports
BRAXIA SCIENTIFIC ANNOUNCES COURT APPROVAL OF CLASS ACTION SETTLEMENT IN CANADA
The Supreme Court of British Columbia has approved a settlement of a class action lawsuit that was filed in May, 2021, against Braxia Scientific Corp., its chief executive officer, as well as certain of its former officers, a shareholder and underwriters. The Canadian settlement contemplates a cash payment of $1.9-million, of which the company will be paying $1.6-million.
The court approval of an agreement in principle (the U.S. settlement) to settle claims alleged in a securities class action (the U.S. class action) against the company and certain of its former officers filed in the United States District Court for the Central District of California in April, 2021, remains pending. The U.S. settlement contemplates a cash payment by the company of $1-million (U.S.) to settle the U.S. class action.
After available insurance, and assuming the court approval of the U.S. settlement is obtained, the total cost to the company to settle both class actions will be approximately $1.36-million.
https://www.stockwatch.com/News/Item/Z-C!BRAX-3306443/C/BRAX
2022-09-16 20:31 ET - News Release
Dr. Roger McIntyre reports
BRAXIA SCIENTIFIC ANNOUNCES COURT APPROVAL OF CLASS ACTION SETTLEMENT IN CANADA
The Supreme Court of British Columbia has approved a settlement of a class action lawsuit that was filed in May, 2021, against Braxia Scientific Corp., its chief executive officer, as well as certain of its former officers, a shareholder and underwriters. The Canadian settlement contemplates a cash payment of $1.9-million, of which the company will be paying $1.6-million.
The court approval of an agreement in principle (the U.S. settlement) to settle claims alleged in a securities class action (the U.S. class action) against the company and certain of its former officers filed in the United States District Court for the Central District of California in April, 2021, remains pending. The U.S. settlement contemplates a cash payment by the company of $1-million (U.S.) to settle the U.S. class action.
After available insurance, and assuming the court approval of the U.S. settlement is obtained, the total cost to the company to settle both class actions will be approximately $1.36-million.
https://www.stockwatch.com/News/Item/Z-C!BRAX-3306443/C/BRAX
Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients
Psilocybin-Assisted Therapy and Research
Braxia Health’s research team progressed the first Phase II randomized Health Canada approved multi-dose psilocybin trial, approved July 2021 and launched November 2021. The trial is expected to be completed by December 2022. Following the preliminary positive results reported earlier this year, which reported meaningful improvements in depression severity observed (as measured by the Montgomery-Åsberg depression rating scale, MADRS), the Company expects to launch additional psilocybin-assisted trials in the coming quarters across multiple diagnostic categories.
KetaMD is currently available in the State of Florida with a roll-out to other key states to begin in 2022.
To date, the Company has steadily grown its ketamine program referral network across 5 cities.
Stock Option Grant
The Company also announced it has granted stock options to certain of its directors, officers and employees to acquire an aggregate of 11,220,000 common shares of the Company. Each option is exercisable into one common share of the Company at an exercise price of $0.08 per Share, being the closing trading price of the shares on the Canadian Securities Exchange on August 26, 2022, for a five-year term expiring on August 29, 2027.
Q1 2023 Financial Summary
The Company’s cash and cash equivalents as of June 30, 2022 was $7.68 million compared with March 31, 2022 at $8.6 million includes cash invested to fund launch of KetaMD and purchase of equipment related to build out of new clinics.
First quarter revenue increased to $0.42 million for the period ending June 30, 2022, up 13% sequentially from $0.37 million in Q4 2022 and up 2.5% from $0.41 million in the comparative prior period. The increase in revenue primarily reflects an increase in the number of treatments from the administering of ketamine at the Braxia Health clinics in Ontario.
Net loss was $0.97 million for the quarter ended June 30, 2022, compared to a net loss of $1.09 million for the three months ended June 30, 2021.
Psilocybin-Assisted Therapy and Research
Braxia Health’s research team progressed the first Phase II randomized Health Canada approved multi-dose psilocybin trial, approved July 2021 and launched November 2021. The trial is expected to be completed by December 2022. Following the preliminary positive results reported earlier this year, which reported meaningful improvements in depression severity observed (as measured by the Montgomery-Åsberg depression rating scale, MADRS), the Company expects to launch additional psilocybin-assisted trials in the coming quarters across multiple diagnostic categories.
KetaMD is currently available in the State of Florida with a roll-out to other key states to begin in 2022.
To date, the Company has steadily grown its ketamine program referral network across 5 cities.
Stock Option Grant
The Company also announced it has granted stock options to certain of its directors, officers and employees to acquire an aggregate of 11,220,000 common shares of the Company. Each option is exercisable into one common share of the Company at an exercise price of $0.08 per Share, being the closing trading price of the shares on the Canadian Securities Exchange on August 26, 2022, for a five-year term expiring on August 29, 2027.
Q1 2023 Financial Summary
The Company’s cash and cash equivalents as of June 30, 2022 was $7.68 million compared with March 31, 2022 at $8.6 million includes cash invested to fund launch of KetaMD and purchase of equipment related to build out of new clinics.
First quarter revenue increased to $0.42 million for the period ending June 30, 2022, up 13% sequentially from $0.37 million in Q4 2022 and up 2.5% from $0.41 million in the comparative prior period. The increase in revenue primarily reflects an increase in the number of treatments from the administering of ketamine at the Braxia Health clinics in Ontario.
Net loss was $0.97 million for the quarter ended June 30, 2022, compared to a net loss of $1.09 million for the three months ended June 30, 2021.
Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health Platform Providing Beneficial Ketamine Treatments in Florida with Plans to Expand Across the U.S.
03. Aug. 2022
Braxia Scientific Corp. is pleased to announce it has acquired 100% of the issued and outstanding stock of KetaMD, Inc. ("KetaMD") (the "Transaction"). KetaMD is a U.S. based, privately-held, innovative telemedicine company, with a mission to address mental health challenges via access to technology-facilitated ketamine-based treatments. KetaMD Logo (CNW Group/Braxia Scientific Corp.) KetaMD's end-to-end telemedicine platform, utilizing leading technology, provides access to safe, affordable, and potentially life-changing at-home ketamine treatments for people suffering from depression and related mental health conditions. Treatments are medically supervised, guided virtually by registered nurses with mental health expertise, and backed by the world's leading psychiatrists and researchers in depression. KetaMD's integration of ketamine and telemedicine is guided by best practices...
https://braxiascientific.com/category/news/
03. Aug. 2022
Braxia Scientific Corp. is pleased to announce it has acquired 100% of the issued and outstanding stock of KetaMD, Inc. ("KetaMD") (the "Transaction"). KetaMD is a U.S. based, privately-held, innovative telemedicine company, with a mission to address mental health challenges via access to technology-facilitated ketamine-based treatments. KetaMD Logo (CNW Group/Braxia Scientific Corp.) KetaMD's end-to-end telemedicine platform, utilizing leading technology, provides access to safe, affordable, and potentially life-changing at-home ketamine treatments for people suffering from depression and related mental health conditions. Treatments are medically supervised, guided virtually by registered nurses with mental health expertise, and backed by the world's leading psychiatrists and researchers in depression. KetaMD's integration of ketamine and telemedicine is guided by best practices...
https://braxiascientific.com/category/news/
Durchsuchen
